A number of firms have modified their ratings and price targets on shares of Astrazeneca PLC (NYSE: AZN) recently:

  • 10/31/2017 – Astrazeneca PLC was given a new $38.00 price target on by analysts at BMO Capital Markets. They now have a “buy” rating on the stock.
  • 10/23/2017 – Astrazeneca PLC had its price target raised by analysts at Leerink Swann from $31.00 to $34.00. They now have a “market perform” rating on the stock.
  • 10/18/2017 – Astrazeneca PLC was upgraded by analysts at Citigroup Inc. to a “buy” rating.
  • 10/17/2017 – Astrazeneca PLC had its “hold” rating reaffirmed by analysts at Cowen and Company. They now have a $37.00 price target on the stock.
  • 10/16/2017 – Astrazeneca PLC was upgraded by analysts at Credit Suisse Group from a “neutral” rating to an “outperform” rating.
  • 9/25/2017 – Astrazeneca PLC was upgraded by analysts at BNP Paribas from a “neutral” rating to an “outperform” rating.
  • 9/22/2017 – Astrazeneca PLC was upgraded by analysts at Sanford C. Bernstein from a “market perform” rating to an “outperform” rating. They now have a $39.00 price target on the stock, up previously from $30.00.
  • 9/22/2017 – Astrazeneca PLC had its “buy” rating reaffirmed by analysts at Sanford C. Bernstein.
  • 9/14/2017 – Astrazeneca PLC was downgraded by analysts at Liberum Capital from a “buy” rating to a “hold” rating.
  • 9/6/2017 – Astrazeneca PLC was upgraded by analysts at Natixis from a “neutral” rating to a “buy” rating.
  • 9/6/2017 – Astrazeneca PLC is now covered by analysts at BMO Capital Markets. They set an “outperform” rating and a $38.00 price target on the stock.

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.